youtube_live
Q3 2026: ieņēmumi • publicēti • Peļņa uz vienu akciju ir lielāka, nekā prognozēts +25,31% • Ieņēmumu mērķis ir pārsniegts +7,89%
Skatīt rezultātuschevron_right
NVO:NYSE
Novo Nordisk A/S
40,30 $
0,00%
(0,00) 1 d.
39,67 $
arrow_downward
-1,56% (-0,63)todayPirmstirdzniecības
Slēgts: 5. nov., 16:00:03 GMT-5 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Tirgus kapitalizācija
138,37 mljrd.
Vid. apjoms
11,90 milj.
Apjoms
376,39 tūkst.
Dividende
4,46%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,54
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,82 $
Beta
0,69
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Tirgus kapitalizācija
138,37 mljrd.
Vid. apjoms
11,90 milj.
Apjoms
376,39 tūkst.
Dividende
4,46%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,54
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,82 $
Beta
0,69
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
News Corp
·
pirms 45 minūtēm
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
The Globe and Mail
·
pirms 9 stundām
NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook
Benzinga
·
pirms 20 stundām
3 Health Care Stocks With Whale Alerts In Today’s Session
Zacks
·
pirms 23 stundām
NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook
Profils
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
SektorsHealth Care
Industry-
Tīmekļa vietnenovonordisk.com